Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT01094249 Completed - Schizophrenia Clinical Trials

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the potential effect of multiple oral doses of an extended release formulation of paliperidone on the pharmacokinetics (blood levels) of valproic acid (VPA) in patients with schizophrenia, bipolar I disorder, or schizoaffective disorder.

NCT ID: NCT01093976 Completed - Clinical trials for Obsessive Compulsive Disorder

Marinol in Trichotillomania or Obsessive Compulsive Disorder

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in individuals with obsessive-compulsive disorder (OCD) or the obsessive-compulsive spectrum disorders, trichotillomania (TTM) or pathological skin picking (PSP). Fifteen patients with OCD, TTM, or PSP will receive 12 weeks of open-label treatment with dronabinol. The hypothesis to be tested is that dronabinol will be effective and well tolerated in patients with these disorders. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

NCT ID: NCT01093768 Completed - Clinical trials for Autism Spectrum Disorders

Brain Imaging Study of Adults With Autism Spectrum Disorders

Start date: February 19, 2010
Phase: Phase 1
Study type: Interventional

This research study investigates the effects of oxytocin and vasopressin on brain activity in adults with Autism Spectrum Disorders using functional magnetic resonance imaging (fMRI). Background: - Oxytocin and vasopressin are two hormones produced in the brain. Both hormones can influence activity in brain regions such as the amygdala that are involved in social and emotional processing. There is evidence suggesting that oxytocin and vasopressin may be implicated in autism spectrum disorders (ASD). Objectives: -Here, we use functional magnetic resonance imaging (fMRI) to assess the effects of oxytocin and vasopressin on brain activity in adult healthy volunteers and adults with ASD. Eligibility: - Right-handed individuals between 18 and 40 years of age who either have been diagnosed with autism, Asperger s disorder, or Pervasive Developmental Disorder- Not Otherwise Specified (PDD-NOS), or are healthy volunteers. Design: - This study requires 3 outpatient visits to the NIH Clinical Center in addition to a screening visit. Each visit will last about 2.5 hours. Participants may not smoke cigarettes or drink alcohol or caffeinated beverages for 12 hours before each visit. - During each visit, participants will receive a nasal spray that contains one of the following: oxytocin, vasopressin, or placebo. Participants will receive a different spray at each visit. - After using the nasal spray, participants will have an MRI scan of the brain while performing tasks with social and emotional stimuli. - After the MRI scan, participants will complete questionnaires about mood and reaction to the tasks, and will remain in the clinic until the effects of the study medication have worn off. - Participants will be contacted 1 day after each MRI scan for follow-up purposes.

NCT ID: NCT01093053 Completed - Anxiety Disorders Clinical Trials

Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations

Start date: September 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether participation in mind-body skills groups by veterans who have experienced a stressful war-related situation and have symptoms of posttraumatic stress disorder (PTSD), will improve symptoms of PTSD, depression and anxiety, reduce anger, improve quality of life, quality of sleep and result in posttraumatic growth (a positive change that people can experience when they have been in a traumatic situation).

NCT ID: NCT01090713 Completed - Clinical trials for Binge Eating Disorder

Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder

Start date: January 2010
Phase: Phase 3
Study type: Interventional

The specific aim of this study is to examine the efficacy and safety of lisdexamfetamine compared with placebo in outpatients with binge eating disorder

NCT ID: NCT01088412 Completed - Clinical trials for Non-GH-deficient Growth Disorders

Observational Study of Somatropin Treatment in Children

GeNeSIS
Start date: April 1999
Phase:
Study type: Observational

GeNeSIS is an open-label, multinational, multicenter, observational study to evaluate the safety and effectiveness of Humatrope treatment. GeNeSIS is a modular program that includes: - Core study: Evaluating the safety and effectiveness of Humatrope in the observational setting - Genetic Analysis Sub-study: Investigating the genetic defects underlying growth hormone (GH) deficiency and non-GH-deficient growth disorders - Growth Prediction Sub-study: Working to validate and refine specific models to accurately predict growth response to GH - Short Stature Homeobox containing gene (SHOX) Deficiency Sub-study: Elucidating the clinical, endocrine and radiological features of participants with SHOX deficiency due to loss of, or mutation in the SHOX gene (including participants with Turner syndrome) - Neoplasia Sub-study: To characterize the natural history of neoplastic disease, especially in relation to recurrence/progression of primary neoplasia or development of secondary neoplasia in children with a history of neoplasia

NCT ID: NCT01086475 Completed - Autistic Disorder Clinical Trials

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

Start date: March 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effectiveness of D-cycloserine for improving social impairment in child with pervasive developmental disorders (PDD).

NCT ID: NCT01085305 Completed - Conduct Disorder Clinical Trials

The Effectiveness of Parent-Child Interaction Therapy (PCIT)

Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of this study was to investigate whether a type of parent-based intervention, Parent-Child Interaction Therapy will lower symptoms of behavior problems in young children more than treatment as usual.

NCT ID: NCT01083823 Completed - Bipolar Disorder Clinical Trials

Calling for Care: Cell Phones for Mood Telemetry in Teens

Start date: March 2010
Phase: N/A
Study type: Interventional

We will modify our existing VMQ/VADIS mood telemetry software to run on a Motorola platform, and enhance it to collect information on both mood symptoms (currently covered by the VMQ/VADIS) as well as daily life stressors (currently outside the VMQ/VADIS' scope). By doing so, we will be able us to examine the role of daily stressors in the lives of teens with and without mood swings, to identify how changes in mood triggered by stressful events are similar to or different from mood changes linked to the bipolar disorder, borderline personality disorder, or other forms of affective instability.

NCT ID: NCT01082588 Completed - Schizophrenia Clinical Trials

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Start date: June 2010
Phase: Phase 4
Study type: Interventional

This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to inflammation in the body. Inflammation poses a risk in developing heart disease, diabetes and problems with brain function. The purpose of this study is to see if pravastatin can: - Lower cholesterol - Decrease inflammation - Improve cognition in patients with schizophrenia